# DESCRIPTION

## BACKGROUND OF THE INVENTION

- describe spinal cord injury
- discuss regeneration in non-mammals

## BRIEF SUMMARY OF THE INVENTION

- disclose HB-EGF compositions
- disclose isolated nucleic acid molecules
- disclose plasmids
- disclose transgene cassettes
- disclose transgenic animals
- disclose vectors
- disclose AAV vectors
- disclose pharmaceutical formulations
- disclose kits
- disclose method of treating spinal cord injury
- disclose method of stimulating regeneration
- disclose method of promoting glial cell proliferation
- disclose method of generating vectors and hydrogels

## DETAILED DESCRIPTION OF THE INVENTION

- introduce invention scope

### A. Definitions

- define scope of invention
- clarify terminology usage
- explain singular and plural forms
- define "consisting essentially of"
- define "consisting of"
- define "comprising"
- explain "about" and ranges
- explain endpoints of ranges
- define "approximately" or "about"
- define "in vitro" and "in vivo"
- define "biomarker"
- explain parts by weight
- define "optional" or "optionally"
- define "subject"
- define "effective amount"
- define "control"
- define "diagnosed"
- define "treat" or "treating" or "treatment"
- define "prevent" or "preventing" or "prevention"
- define CRISPR and its components
- define CRISPRa and CRISPRi
- define dCas9 and its variants
- define PAM and its role
- describe CRISPR-based endonucleases and their properties
- list examples of CRISPR/Cas proteins and their sources
- describe RNA recognition and binding domains
- describe modifications to CRISPR/Cas proteins
- define promoter and its types
- list examples of tissue-specific promoters
- define ubiquitous/constitutive promoters and their examples
- define inducible promoters and their regulation
- define operably linked and its significance
- define enhancer and its role
- define expression cassette, isolated biological component, and sequence identity

### B. Compositions

- define HB-EGF compositions
- describe recombinant HB-EGF
- specify HB-EGF sequences
- describe HB-EGF functions
- introduce isolated nucleic acid molecules
- describe TREE elements
- specify promoter sequences
- describe Hsp70 promoters
- describe Hsp68 promoters
- describe cfos promoters
- describe AAV e1B promoters
- describe CMV promoters
- describe Thy1 promoters
- describe GFAP promoters
- describe FoxJ1 promoters
- describe encoded polypeptides
- specify transcription factors
- describe secreted factors
- describe TREE functions
- describe reporter genes
- describe viral vectors
- define plasmids
- describe transgene cassette
- describe transgenic animals
- describe cells
- define vectors
- describe vector components
- describe AAV vectors
- describe vector applications
- describe CRISPR-based epigenome editing tools
- describe gRNAs
- describe promoters
- define pharmaceutical formulations
- describe formulation components
- describe HB-EGF formulations
- describe pharmaceutically acceptable carriers
- define kits
- describe kit components
- describe kit applications
- describe kit instructions

### C. Methods

- define method of treating spinal cord injury
- administer isolated nucleic acid molecule
- administer vector
- administer pharmaceutical formulation
- stimulate regeneration of spinal cord tissue
- promote glial cell proliferation
- promote axonal tract regeneration
- trigger neurite outgrowth
- trigger neuron formation
- improve spinal cord function
- administer HB-EGF
- specify HB-EGF types
- administer HB-EGF with isolated nucleic acid molecule
- administer HB-EGF with vector
- administer HB-EGF with pharmaceutical formulation
- apply hydrogel to injured spinal cord tissue
- specify hydrogel therapeutic agents
- apply HB-EGF to injured spinal cord tissue
- administer isolated nucleic acid molecule or vector systemically
- administer HB-EGF or pharmaceutical formulation systemically
- monitor subject for adverse effects
- define spinal cord tissue
- specify neuroglia types
- describe method of administering HB-EGF
- outline therapeutic agents
- monitor adverse effects
- generate viral or non-viral vector
- prepare hydrogel
- describe method of promoting glial cell proliferation
- specify HB-EGF types
- outline method of stimulating regeneration
- describe method of promoting axonal tract regeneration
- specify HB-EGF types
- outline method of stimulating regeneration
- describe reducing inflammation and scar tissue
- summarize method of promoting axonal tract regeneration
- define hydrogel composition
- describe therapeutic agents
- outline administration methods
- detail HB-EGF application
- describe promoter function
- outline spinal cord tissue composition
- describe repeating administration
- outline additional therapeutic agents
- describe monitoring adverse effects
- outline generating viral or non-viral vector
- describe preparing hydrogel
- outline spatiotemporally targeted tissue regeneration
- describe method of triggering neurite outgrowth
- describe method of triggering neuron formation
- outline improving spinal cord function
- describe method of improving spinal cord function with HB-EGF
- define method of improving spinal cord function
- describe HB-EGF composition
- describe method of improving spinal cord function
- describe administering HB-EGF
- describe hydrogel application
- describe therapeutic agent administration
- describe monitoring adverse effects
- describe generating viral or non-viral vector
- describe preparing hydrogel
- describe spatiotemporally targeted tissue regeneration
- define method of generating non-viral or viral vector
- describe generating AAV vector
- define method of generating hydrogel
- describe synthesizing UPy-bearing linker
- define method of identifying putative TREEs
- describe isolating nuclei from spinal cord cells
- describe validating putative TREE

## EXAMPLES

- illustrate spinal cord regeneration

### A. Materials and Methods

- describe zebrafish strains and ages used
- generate transgenic and mutant lines
- generate GFAP:H2B-mCherry zebrafish
- generate hb-egfa:EGFP zebrafish
- generate hb-egfb:EGFP zebrafish
- generate hb-egfaKO and hb-egfbKO zebrafish
- generate hsp70:shb-egfa-P2A-TBFP zebrafish
- generate hb-egfaEN-cfos:EGFP and cfos:EGFP zebrafish
- describe spinal cord injuries in zebrafish
- describe RNA- and ATAC-sequencing
- describe RNA isolation and qRT-PCR
- describe Western blotting
- describe Edu, biocytin, and HR-HB-EGF treatment
- describe generation of synthetic biomaterials for local HR-HB-EGF delivery
- describe synthesis of UPy-bearing linker
- describe synthesis of HA-UPy
- describe synthesis of FITC conjugated HA-Upy (HA-Upy-FITC)
- describe oxidation of HA-UPy
- quantify aldehyde content in HA-UPy-DA
- describe hydrogelation and growth factor loading
- describe histological analysis in zebrafish
- describe swim capacity assays
- describe handling of mice
- describe spinal cord injuries in mice
- describe histological analyses in mice
- describe virus production and titers
- describe data analyses and statistics
- describe quantification of cells co-expressing EGFP and GFAP
- describe statistical tests

### B. Specific Examples

- introduce HB-EGF paralogues in zebrafish spinal cord regeneration
- describe expression profiling experiment for genes induced during regeneration
- motivate HB-EGF as a secreted glycoprotein
- summarize previous studies on HB-EGF in MÃ¼ller glial cell dedifferentiation
- describe in situ hybridization (ISH) results for hb-egfa and hb-egfb transcripts
- introduce CRISPR/Cas9 methods for generating hb-egf mutants
- evaluate effects of hb-egf mutations on spinal cord regeneration
- perform EdU incorporation assays to measure cell proliferation
- measure tissue bridging and axon regeneration
- assess swim capacity in hb-egfdKO animals
- introduce reporter lines to visualize cell types expressing hb-egf paralogs
- describe fluorescence patterns in hb-egfa:EGFP and hb-egfb:EGFP fish
- assess which paralog has prominent functions in spinal cord regeneration
- evaluate effects of hb-egfa and hb-egfb single mutants on regeneration
- describe polarized distribution of hb-egfa mRNA or hb-egfa:EGFP expression
- disrupt polarized expression using a soluble form of hb-egfa
- assess effects of targeted Hb-egf augmentation to the lesion site
- identify regulatory TREEs relevant to spinal cord regeneration using ATAC-seq
- test whether hb-egfaEN can direct injury-induced gene expression after spinal cord injury
- implicate transcription factors that regulate hb-egfa expression

## SUMMARY OF EXPERIMENTAL RESULTS

- identify Hb-egfa as instructive factor
- analyze TREEs in regeneration programs
- discuss applications of TREE-based delivery systems

